Browsing by Author Dimopoulos, Meletios A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2017Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Hajek, Roman; Ludwig, Heinz; Moreau, Philippe; Niesvizky, R.; Pour, Ludek; Central Clinical School: MedicineCarfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup, Leukemia & Lymphoma, vol.58, 10, 2017,pp 2501-2504
2017Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Hajek, Roman; Ludwig, Heinz; Niesvizky, R.; Oriol, Albert; Orlowski, Robert Z; Central Clinical School: MedicineCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 10, 2017,pp 1327-1337
2017Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Ludwig, Heinz; Moreau, Philippe; Niesvizky, R.; Palumbo, Antonio; Pour, Ludek; Central Clinical School: MedicineCarfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR, Leukemia, vol.31, 6, 2017,pp 1368-1374
2016International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentJoshua, Douglas; Dimopoulos, Meletios A; Durie, Brian G M; et al, Various; Garderet, Laurent; Goldschmidt, Hartmut; Kastritis, Efstathios; Leung, Nelson; Ludwig, Heinz; Merlini, Giampaolo; Orlowski, Robert Z; Powles, Ray; Rajkumar, S Vincent; Richardson, Paul G; Sonneveld, Pieter; Vesole, David H.; Central Clinical School: MedicineInternational Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment, Journal of Clinical Oncology, vol.34, 13, 2016,pp 1544-1557
2018Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's MacroglobulinemiaTrotman, Judith; Buske, C; Dimopoulos, Meletios A; Garcia-Sanz, Ramon; Graef, T; Herbaux, Charles; Kastritis, Efstathios; Leblond, Veronique; Li, J; Macdonald, David; Mahe, Beatrice; Matous, J; Orsucci, Lorella; Palomba, M Lia; Salman, Zeena; Shustik, C; Tam, C; Tedeschi, A; Treon, S; Concord Clinical School: MedicinePhase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia, New England Journal of Medicine, vol.378, 25, 2018,pp 2399-2410